BetterScholar BetterScholar
6
Role
Title
Level Year L/R
🐜 Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
25 auth. J. I. Fernández-Velasco, J. Kuhle, E. Monreal, V. Meca-Lallana, J. Meca-Lallana, G. Izquierdo, F. Gascón-Giménez, S. Sainz de la Maza, P. Walo-Delgado, A. Maceski, E. Rodríguez-Martín, E. Roldán, N. Villarrubia, A. Saiz, Y. Blanco, ... P. Sánchez, E. Carreón-Guarnizo, Y. Aladro, L. Brieva, C. Íñiguez, I. González-Suárez, L. A. Rodríguez de Antonio, J. Masjuán, L. Costa-Frossard, L. Villar
5 2021
5
🐜
🐜 Possible Influence of the Route of Treatment Administration on Treatment Adherence in Patients With Multiple Sclerosis.
7 auth. I. Sánchez Martínez, María Cerdán Sánchez, J. López Román, F. Iniesta Martínez, E. Carreón-Guarnizo, J. M. Meca Lallana, ... Pilar Zafrilla Rentero
4 2020
4
🐜
🐜 Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis.
13 auth. Naresh Mutukula, Zhiqiu Man, Yuta Takahashi, F. Iniesta Martínez, Mariana Morales, E. Carreón-Guarnizo, R. Hernández Clares, D. García-Bernal, Llanos Martinez Martinez, J. Lajara, ... Estrella Nuñez Delicado, J. M. Meca Lallana, J. I. Izpisúa Belmonte
3 2021
3
🐜
🐢 Spasticity in multiple sclerosis and role of glatiramer acetate treatment
J. Meca-Lallana, R. Hernández-Clares, E. Carreón-Guarnizo
3 2015
3
🐢
🐜 Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
10 auth. Luna Fuentes-Rumí, R. Hernández-Clares, E. Carreón-Guarnizo, G. Valero-López, F. Iniesta-Martinez, J. M. Cabrera-Maqueda, ... A. León-Hernández, J. Zamarro-Parra, A. Morales-Ortíz, J. Meca-Lallana
3 2020
3
🐜
🦁 [Prevalence of multiple sclerosis in the Region of Murcia].
12 auth. E. Carreón-Guarnizo, E. Andreu-Reinon, M. Cerdán-Sánchez, R. Carrasco-Torres, R. Hernández-Clares, L. Prieto-Valiente, ... C. Garcia-Escriba, A. Sola-Roca, M. E. Martinez-Andreu, M. Miralles González-Conde, J. Martín-Fernández, J. Meca-Lallana
2 2016
2
🦁